Vimian Group AB (VIMIAN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vimian Group AB (VIMIAN) has a cash flow conversion efficiency ratio of 0.080x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr56.57 Million ≈ $6.09 Million USD) by net assets (Skr708.80 Million ≈ $76.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VIMIAN equity financing ratio to measure how much of total assets are equity-financed.
Vimian Group AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vimian Group AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vimian Group AB (VIMIAN) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Vimian Group AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vimian Group AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
0.055x |
|
Shenzhen Airport Co Ltd
SHE:000089
|
0.037x |
|
Ningxia Jiaze Renewables Corp
SHG:601619
|
0.189x |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
0.078x |
|
Telecom Argentina
BA:TECO2
|
0.156x |
|
Yangtze Optical Electronic Co. Ltd. A
SHG:688143
|
N/A |
|
Hpsp Co Ltd
KQ:403870
|
0.044x |
|
Federal Agricultural Mortgage Corporation
NYSE:AGM
|
0.054x |
Annual Cash Flow Conversion Efficiency for Vimian Group AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vimian Group AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Vimian Group AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr708.80 Million ≈ $76.28 Million |
Skr105.70 Million ≈ $11.38 Million |
0.149x | +81.34% |
| 2024-12-31 | Skr706.50 Million ≈ $76.03 Million |
Skr58.10 Million ≈ $6.25 Million |
0.082x | +251.58% |
| 2023-12-31 | Skr526.71 Million ≈ $56.68 Million |
Skr-28.58 Million ≈ $-3.08 Million |
-0.054x | -203.20% |
| 2022-12-31 | Skr481.50 Million ≈ $51.82 Million |
Skr25.31 Million ≈ $2.72 Million |
0.053x | +17.74% |
| 2021-12-31 | Skr358.64 Million ≈ $38.60 Million |
Skr16.01 Million ≈ $1.72 Million |
0.045x | +155.06% |
| 2020-12-31 | Skr274.25 Million ≈ $29.51 Million |
Skr4.80 Million ≈ $516.66K |
0.018x | -41.17% |
| 2019-12-31 | Skr52.02 Million ≈ $5.60 Million |
Skr1.55 Million ≈ $166.59K |
0.030x | +128.80% |
| 2018-12-31 | Skr19.59 Million ≈ $2.11 Million |
Skr-2.02 Million ≈ $-217.81K |
-0.103x | -- |
About Vimian Group AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic… Read more